C4x Discovery Share Discussion Threads

[alloa2003] 30/3/2020 06:58

Might we see some kind of announcement this week about a deal?

[albert arthur] 27/3/2020 19:25

Oral NRF-2 activator programmeC4XD has designed and discovered novel potent activators of the NRF-2 pathway, which is important in mediating lung diseases such as Sickle Cell Disease ("SCD"), chronic obstructive pulmonary disease ("COPD"), pulmonary arterial hypertension ("PAH"), and other inflammatory diseases. Multiple C4XD compounds have shown >12 hour NRF-2 activation in the lungs and other target tissues following low dose oral administration in pre-clinical studies. These novel compounds are being optimised for solubility and pharmacokinetic properties for pre-clinical candidate short-list selection. Pre-clinical data suggests that the anti-oxidant and anti-inflammatory activity provided by NRF-2 activators may ameliorate haemolysis-related complications in SCD such as severe pain episodes, organ damage, heart attacks and stroke and the $41 million COPD market represents an area of substantial unmet medical need.https://www.c4xdiscovery.com/inflammation-programmes.html

[adamfletcher1] 27/3/2020 18:44

NADS in COVID-19 - short communication - version 1.1 - 1.5 A4 pages without references - 26.03.2020) Potent NRF2-activating dietary supplements (like resveratrol, curcumin, sulforaphane, "Asea redox supplement" [ARS] etc.) should be clinically tested as high-dose adjuvants in all types of medium and severe cases of aggressive respiratory viral infections (including Influenza A/B/C, measles, Coronavirus-related SARS, MERS, COVID-19) based on their extrapolated cytoprotective antioxidant effectsPreprint (PDF Available) · February 2020?with?557 Reads?DOI: 10.13140/RG.2.2.33764.12163Cite this publicationAndrei-Lucian Dragoi at Spitalul Judetean de Urgenta Targoviste (SJUT), Dâmbovi?a, RomaniaAndrei-Lucian Dragoi4.65Spitalul Judetean de Urgenta Targoviste (SJUT), Dâmbovi?a, RomaniaAbstractThis very short medical communication proposes that potent NRF2-activating dietary supplements (like resveratrol, sulforaphane, curcumin, "Asea redox supplement" [ARS] etc.) should be clinically tested as safe high-dose adjuvants (in various combinations) in all types of medium and severe cases of aggressive respiratory viral infections (including Influenza A/B/C, avian influenza, measles, Coronavirus-related SARS, MERS, COVID-19, etc., including those patients who have important comorbidities like HIV/AIDS, tuberculosis [TB] etc.) based on their extrapolated cytoprotective antioxidant effects (especially on the main vital organs: brain, heart, lungs, kidneys and liver), including the extrapolated strong cytoprotection offered by ARS on the cardiac muscle of DMD patients (which can be extrapolated to the lungs), like the author of this paper has demonstrated in past papers. Keywords: NRF2-activating dietary supplements, resveratrol, sulforaphane, curcumin, "Asea redox supplement" [ARS], respiratory viral infections, influenza A/B/C, avian influenza, measles, coronavirus, SARS, MERS, COVID-19, HIV/AIDS, tuberculosis [TB]

[albert arthur] 27/3/2020 17:34

The join the dots from post 1147

[albert arthur] 27/3/2020 17:32

NRF2 molecule makes body's defense mechanism stronger, effective in combating viruses, says doctorThere is an NRF2 molecule in the human body. This molecule reveals systems that expand the body's ability to fight viruses. During this period, we need to consume broccoli, turmeric, grapes, rosemary and food containing zinc to increase NRF2 level in our body.Clinical trials coming for NRF2 for COVID-19. Surely.Watch this from 4 mins 15 secs:https://youtu.be/JdFIoehnEZI

[albert arthur] 27/3/2020 17:29

NRF2 molecule makes body's defense mechanism stronger, effective in combating viruses, says doctorThere is an NRF2 molecule in the human body. This molecule reveals systems that expand the body's ability to fight viruses. During this period, we need to consume broccoli, turmeric, grapes, rosemary and food containing zinc to increase NRF2 level in our body.Clinical trials coming for NRF2 for COVID-19. Surely.Watch this from 4 mins 15 secs:C4X Discovery fully cashed up and sees big potential for its 'blockbuster molecules'

[alloa2003] 27/3/2020 12:56

Thanks DaveMac3, sorry I used the wrong terminology not antibodies should be molecules. However, was the whole point of C4XD the fact they are using current molecules for different treatments so no need for full FDA clearance again?

[the stigologist] 27/3/2020 12:53

C4XD Mkt Cap £13m
INDV Mkt Cap £400-500m

INDV agreed to pay C4XD $294m in milestones/royalties etc if INDV2000 makes it to market

So IF INDV survives DoJ attack it will make sense for them to buy C4XD at any price less than $294m ! That's almost a built in potential 5x 10x bagger

[davemac3] 26/3/2020 23:07

alloa, the Indivior compound is a small molecule (oral drug) and not an antibody. C4XD are AFAIAA completely a small molecule company and don't do any antibody research

[the stigologist] 26/3/2020 16:55

WTF! WTF!! WTF !!!

Did anybody know this ?

INDV got a $10m grant from the US Government NIH HEAL Fund to advance their C4XD product !!!

INDV who have $1bn cash on their Balance Sheet !!!

INDV who only paid $10m upfront cash to C4XD to licence this Orexin-1 antagonist !!!

This is HUGE news to me

Demonstrate US Govt interest and intention to push this programme

The science must clearly be A1

[f3rdinand] 26/3/2020 16:49

I think you're thinking of N4P? Before they went bust

[alloa2003] 26/3/2020 16:41

I thought the whole point of the C4XD system was that it was just tweaking and reusing antibodies which have already been approved for (sometimes different) use and for which there was already plenty of data. On that basis I dont see why the FDA would have any major issues?

[the stigologist] 26/3/2020 16:19

"Once an IND is submitted, the FDA has 30 days to object to the IND or it automatically becomes effective and clinical trials may begin."

Well it's been 60 days so given no announcement of Clinical Trials beginning I'm assuming there were objections raised.

However we are now 60+ days so one would hope resolved soon/imminently

[the stigologist] 26/3/2020 16:16

What would have been 'small' in 2018 when C4XD was a £100m+ Company will probably be quite substantial in this new world

[davemac3] 26/3/2020 16:07

we don't know what the milestones are with Indivior. I suspect there may be a small payment for the start of Phase 1 but not certain.

[the stigologist] 26/3/2020 15:59

This was from INDV Research bulletin in January... clearly progressing

zero mention from C4XD

[alloa2003] 26/3/2020 15:05

The beauty is that if INDV is breaking out on the C4XD antibody deal progressing then they wont want to delay it by playing silly games over milestone payments (and there is nowhere to hide if they start this).

[f3rdinand] 26/3/2020 14:34

I've always had it I mind that April/May are going to be big months for C4XD on multiple fronts! Should really be at 50p plus (given the dilution) at this point and ready to spring back to a pound on new licence deals! Total bargain at 12p- laughable really

[the stigologist] 26/3/2020 14:25

WOW

INDV is breaking out

[alloa2003] 26/3/2020 11:52

Shortage of stock which suggests news on the way.

[f3rdinand] 26/3/2020 10:42

Very interesting. Mm's will take 150k off me at 11.5p which for this share is very unusual- suggests a buyer in the background or they want shares for another purpose?